[go: up one dir, main page]

UY32142A - Preparación de una quinoliniloxidifenilciclopropanodicarboxamida - Google Patents

Preparación de una quinoliniloxidifenilciclopropanodicarboxamida

Info

Publication number
UY32142A
UY32142A UY0001032142A UY32142A UY32142A UY 32142 A UY32142 A UY 32142A UY 0001032142 A UY0001032142 A UY 0001032142A UY 32142 A UY32142 A UY 32142A UY 32142 A UY32142 A UY 32142A
Authority
UY
Uruguay
Prior art keywords
preparation
quinoliniloxidifenilciclopropanodicarboxamida
compound
relates
present
Prior art date
Application number
UY0001032142A
Other languages
English (en)
Inventor
Zhou Xiaoming
Nicole Marie Deschamps
Michael Tolar Martin
Michael John Monteith
Original Assignee
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beckman Corp filed Critical Smithkline Beckman Corp
Publication of UY32142A publication Critical patent/UY32142A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a un procedimiento para preparar un compuesto de la fórmula III siguiente: en el que R1-R4 son como se define en la presente memoria. La presente invención también se refiere a la preparación de compuestos intermedios usados para preparar el compuesto de fórmula III:
UY0001032142A 2008-09-26 2009-09-24 Preparación de una quinoliniloxidifenilciclopropanodicarboxamida UY32142A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10045208P 2008-09-26 2008-09-26

Publications (1)

Publication Number Publication Date
UY32142A true UY32142A (es) 2010-05-31

Family

ID=42058136

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032142A UY32142A (es) 2008-09-26 2009-09-24 Preparación de una quinoliniloxidifenilciclopropanodicarboxamida

Country Status (8)

Country Link
US (1) US8314232B2 (es)
EP (1) EP2339918A4 (es)
JP (1) JP5587324B2 (es)
CN (1) CN102227164A (es)
AR (1) AR075084A1 (es)
TW (1) TW201035017A (es)
UY (1) UY32142A (es)
WO (1) WO2010036831A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009303602B2 (en) 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
MX2011007620A (es) 2009-01-16 2011-11-04 Exelixis Inc Sal de malato de n(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n '-(4-fluorofenil) ciclopropano-1,1-dicarboxamida, y sus formas cristalinas para el tratamiento de cancer.
RU2011142597A (ru) 2009-03-21 2013-04-27 Саншайн Лейк Фарма Ко., Лтд. Производные сложных эфиров аминокислот, их соли и способы применения
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
JP5795630B2 (ja) * 2010-04-29 2015-10-14 デシフェラ ファーマシューティカルズ，エルエルシー 抗癌及び抗増殖活性を示すシクロプロピルジカルボキサミド及び類似体
DK2593090T3 (da) 2010-07-16 2021-10-25 Exelixis Inc Farmaceutiske C-MET-modulator-sammensætninger
PT2621481T (pt) 2010-09-27 2019-11-19 Exelixis Inc Inibidores duplos de met e vegf para o tratamento de cancro da próstata resistente à castração e metástases ósseas osteoblásticas
GEP20217235B (en) 2011-02-10 2021-03-25 Inc Exelixis Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
JP2014513129A (ja) 2011-05-02 2014-05-29 エクセリクシス， インク． 癌および骨癌疼痛の治療方法
EP3275443A1 (en) 2011-09-22 2018-01-31 Exelixis, Inc. Method for treating osteoporosis
US9365516B2 (en) * 2011-10-20 2016-06-14 Exelixis, Inc. Process for preparing quinoline derivatives
EP2844254A1 (en) 2012-05-02 2015-03-11 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
CN103664776B (zh) * 2012-09-26 2016-05-04 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
CN102977014B (zh) * 2012-11-05 2015-01-07 沈阳药科大学 新的喹啉类化合物及其用途
CN102964308B (zh) * 2012-11-30 2015-03-18 中国药科大学 新型嘧啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
CN103044263A (zh) * 2013-01-14 2013-04-17 中国药科大学 一种治疗囊性纤维化药物的中间体的制备方法
CN103965104B (zh) * 2013-01-29 2017-09-29 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
GEP20196995B (en) 2013-03-15 2019-07-25 Inc Exelixis Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
EP2981263B1 (en) 2013-04-04 2022-06-29 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
EA032757B1 (ru) 2014-02-14 2019-07-31 Экселиксис, Инк. Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
EP3119476A1 (en) 2014-03-17 2017-01-25 Exelixis, Inc. Dosing of cabozantinib formulations
EP3174854B1 (en) 2014-07-31 2022-08-24 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
JP6892381B2 (ja) 2014-08-05 2021-06-23 エグゼリクシス， インコーポレイテッド 多発性骨髄腫を治療するための薬物の組み合わせ
CN105218445B (zh) * 2015-08-25 2018-05-22 江苏中邦制药有限公司 一种酪氨酸激酶抑制剂Foretinib的制备方法
RU2748549C2 (ru) 2016-04-15 2021-05-26 Экселиксис, Инк. Способ лечения почечно-клеточного рака с использованием n-(4-(6,7-диметоксихинолин-4-илокси)фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, (2s)-гидроксибутандиоата
CN110117254B (zh) * 2019-06-20 2022-05-13 江苏君若药业有限公司 卡博替尼的制备方法
CN112194622A (zh) * 2020-09-24 2021-01-08 上海毕得医药科技有限公司 一种5-氯喹啉-4-醇的合成方法
WO2024110606A1 (en) 2022-11-25 2024-05-30 Synthon B.V. A process for preparation of cabozantinib or tivozanib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2392564T1 (sl) * 2003-09-26 2014-02-28 Exelixis, Inc. c-Met modulatorji in postopki uporabe
EP1711495A2 (en) * 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer

Also Published As

Publication number Publication date
EP2339918A1 (en) 2011-07-06
WO2010036831A1 (en) 2010-04-01
JP2012503671A (ja) 2012-02-09
CN102227164A (zh) 2011-10-26
US8314232B2 (en) 2012-11-20
EP2339918A4 (en) 2012-06-06
TW201035017A (en) 2010-10-01
US20100081805A1 (en) 2010-04-01
AR075084A1 (es) 2011-03-09
JP5587324B2 (ja) 2014-09-10

Similar Documents

Publication Publication Date Title
UY32142A (es) Preparación de una quinoliniloxidifenilciclopropanodicarboxamida
IN2012DN02751A (es)
CU20110052A7 (es) Compuestos orgánicos
MX377930B (es) Proceso para fabricar compuestos de quinolona.
HN2011000341A (es) Compuestos derivados de sulfonamidas, composiciones farmaceuticos y proceso de preparacion de los mismos
UY31367A1 (es) Derivados de nicotinamida, su preparacion y su aplicacion en terapeutica
MX2019003738A (es) Compuestos antivirales.
ECSP10010434A (es) Inhibidores de hsp90
CU24354B1 (es) Procedimiento de obtención de derivados de tetrafluoropropilmorfolina
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
NI201100078A (es) Proceso para la preparación de derivados de l-alanina protegidos.
EP2590649A4 (en) PROCESS FOR SYNTHESIS OF SUBSTITUTED MORPHINANES
UY32517A (es) Derivados de nicotinamida, su preparación y su aplicación en terapéutica
BR122018074319B8 (pt) Método para preparar um composto de fórmula 14
MX2012001411A (es) Proceso para la preparacion de derivados de acido 1-(2-halobifenil-4-il)-ciclopropanocarboxilico.
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
CR20120592A (es) Intermedios de agomelatina y métodos de preparación de estos
CR20110208A (es) Proceso para la preparación de benzonorbornenos
CY1119697T1 (el) Μεθοδος παρασκευης ενωσεων α-γαλακτοζυλο κεραμιδιων
MX2010009926A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexancarboxilico.
MX2020009462A (es) Procesos para la preparación de compuestos de pirimidinilciclopentano.
UY35766A (es) Proceso industrial para la síntesis de ingredientes activos esteroides
MX2013004193A (es) Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico.
BR112012008952A2 (pt) microbicidas
MX2013002656A (es) Nuevo proceso.

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20101124